1UNAIDS. World AIDS Day Report[EB/OL]. Geneva: UN- AIDS, 2012 (2012-12-11) [2014-8-30] http://www, unaids. org/ en/ media/ unaids/ contentassets/ documents/ epidemiolo- gy/2012/gr2012/JC2434_World AIDS day_results_en, pdf.
2Troll JG. Approach to dyslipidemia, lipodystrophy, and cardio- vascular risk in patients with HIV infection[J]. Curr Athero- scler Rep, 2011, 13(1) :51-56.
3Friis-Moller N,Sabin CA,Weber R,et al. Combination antiret- roviral therapy and the risk of myocardial infarction[J]. N En- gl J Med, 2003, 349(21):1993-2003.
4Tseng ZH,Secemsky EA,Dowdy D,et al. Sudden cardiac death in patients with human immunodeficiency virus infection[J]. J Am Coil Cardiol, 2012, 59(21) : 1891-1896.
5Saves M, Chene G, Ducimetiere P, et al. Risk factors for coro- nary heart disease in patients treated for human immunodefi- ciency virus infection compared with the general population [J]. Clin Infect Dis, 2003, 37(2):292-298.
7Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk fac- tors and treatment[J].Scand J Infect Dis, 2000, 32(2) : 111- 123.
8Rose H, Woolley I, Hoy J, et al. HIV infection and high-density lipoprotein:the effect of the disease vs the effect of treatment [J]. Metabolism, 2006, 55(1) : 90-95.
9de Almeida ER~Reiche EM,Kallaur AP,et al. The roles of ge- netic polymorphisms and human immunodeficiency virus infec- tion in lipid metabolism[J]. Biomed Res Int, 2013, 2013 : 1- 15.
10EI-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large an- tiretroviral-naive cohord[J]. HIV Med, 200S, 6(2):114-121.
